Evidence map›Paper›PMID 34130714›Full record

ArticleJournal of translational medicine2021

Inhibition of c-Fos expression attenuates IgE-mediated mast cell activation and allergic inflammation by counteracting an inhibitory AP1/Egr1/IL-4 axis.

Hui-Na Wang, Kunmei Ji, Li-Na Zhang, Chu-Chu Xie, Wei-Yong Li, Zhen-Fu Zhao, Jia-Jie Chen

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Up-regulation of NGEF via the BRAFBiochemistry and biophysics reports · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hui-Na Wang *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.
Kunmei Ji *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.ORCID 0000-0002-5754-8697
Li-Na ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.
Chu-Chu XieDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.
Wei-Yong LiDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.
Zhen-Fu ZhaoDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China.
Jia-Jie ChenDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Laboratory Department of South China Hospital, Health Science Center, Shenzhen University, No. 1066 Xueyuan Road, Nanshan District, Shenzhen, 518060, People's Republic of China. chenjj@szu.edu.cn.ORCID 0000-0002-1372-8450
Shenzhen University Health Science Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivator protein-1 (AP1), a c-Fos-JUN transcription factor complex, mediates many cytobiological processes. c-Fos has been implicated in immunoglobulin (Ig)E activation of mast cells (MCs) via high-affinity IgE Fc receptor (FcεRI) binding. This study examined c-Fos involvement in MC activation and tested the effects of the c-Fos/AP1 inhibitor T-5224 on MCs activation and allergic responses.

methodsIn vitro studies were conducted with two MC model systems: rat basophilic leukemia cells (RBLs) and mouse bone marrow derived mast cells (BMMCs). MC degranulation and effector functions were examined with β-hexosaminidase release and cytokine secretion assays. c-Fos/AP1 was inhibited with T-5224. c-Fos activity was suppressed with short hairpin RNA targeting c-Fos (shFos). In vivo immune responses were evaluated in passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models, as well as in an oxazolone (OXA)-induced model of atopic dermatitis, a common allergic disease.

resultsc-Fos expression was elevated transcriptionally and translationally in IgE-stimulated MCs. c-Fos binding of the Egr1 (early growth response 1) promoter upregulated Egr1 transcription, leading to production of interleukin (IL)4. T-5224 reduced FcεRI-mediated MC degranulation (evidenced by β-hexosaminidase activity and histamine levels) and diminished EGR1 and IL4 expression. T-5224 attenuated IgE-mediated allergic responses in PCA and ASA models, and it suppressed MC-mediated atopic dermatitis in mice.

conclusionIgE binding can activate MCs via a c-Fos/Egr1/IL-4 axis. T-5224 suppresses MC activation in vitro and in vivo and thus represents a promising potential strategy for targeting MC activation to treat allergic diseases.

Indexed as

AnaphylaxisMast CellsAnimalsCell DegranulationEarly Growth Response Protein 1Immunoglobulin EInflammationInterleukin-4MiceRatsTranscription Factor AP-1Early Growth Response Protein 1Egr1 protein, mouseEgr1 protein, ratImmunoglobulin EInterleukin-4Transcription Factor AP-1c-FosEgr1FcεRI signalingMast cellsT-5224

Identifiers

PMID34130714
PMCPMC8207675
OpenAlexW3134976363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.